Global HIV/AIDS clinical and translational pharmacology

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Morse, Gene D ^a,b   Maartens, Gary ^c   Maponga, Charles Chiedza ^a,d   Ma, Qing ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873864055     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/973627     Document Type: Editorial

References (41)

1. Lima V. D., Johnston K., Hogg R. S., Levy A. R., Harrigan P. R., Anema A., Montaner J. S. G., Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. Journal of Infectious Diseases 2008 198 1 59 67 2-s2.0-46349100736 10.1086/588673 (Pubitemid 351920290)
2. Montaner J. S., Hogg R., Wood E., Kerr T., Tyndall M., Levy A. R., Harrigan P. R., The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. The Lancet 2006 368 9534 531 536 2-s2.0-33746512140 10.1016/S0140-6736(06)69162-9 (Pubitemid 44142776)
3. Wood E., Montaner J. S. G., Bangsberg D. R., Tyndall M. W., Strathdee S. A., O'Shaughnessy M. V., Hogg R. S., Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 2003 17 17 2419 2427 2-s2.0-1442291565 10.1097/00002030-200311210-00003 (Pubitemid 38393313)
4. Sarna A., Kellerman S., Access to antiretroviral therapy for adults and children with HIV infection in developing countries: horizons studies, 2002-2008. Public Health Reports 2010 125 2 305 315 2-s2.0-77950347696
5. Glass T.R., Rotger M., Telenti A., Decosterd L., Csajka C., Bucher H. C., Günthard H. F., Rickenbach M., Nicca D., Hirschel B., Bernasconi E., Wandeler G., Battegay M., Marzolini C., Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. PLoS ONE 2012 7 1 e29186 10.1371/journal.pone.0029186
6. Gandhi R. T., Coombs R. W., Chan E. S., Bosch R. J., Zheng L., Margolis D. M., Read S., Kallungal B., Chang M., Goecker E. A., Wiegand A., Kearney M., Jacobson J. M., D'Aquila R., Lederman M. M., Mellors J. W., Eron J. J., No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. JAIDS 2011 59 3 229 235 10.1097/QAI.0b013e31823fd1f2
7. Dinoso J. B., Kim S. Y., Wiegand A. M., Palmer S. E., Gange S. J., Cranmer L., O'Shea A., Callender M., Spivak A., Brennan T., Kearney M. F., Proschan M. A., Mican J. M., Rehm C. A., Coffin J. M., Mellors J. W., Siliciano R. F., Maldarelli F., Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 2009 106 23 9403 9408 2-s2.0-67249121143 10.1073/pnas.0903107106
8. Siliciano R. F., Latency and reservoirs for HIV-1. AIDS 1999 13 supplement A S49 58 2-s2.0-0010977793
9. Smith M. Z., Wightman F., Lewin S. R., HIV reservoirs and strategies for eradication. Current HIV/AIDS Reports 2012 9 1 5 15 10.1007/s11904-011-0108-2
10. Chun T. W., Murray D., Justement J. S., Hallahan C. W., Moir S., Kovacs C., Fauci A. S., Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. Journal of Infectious Diseases 2011 204 1 135 138 2-s2.0-79957966626 10.1093/infdis/jir208
11. Chun T. W., Fauci A. S., Latent reservoirs of HIV: obstacles to the eradication of virus. Proceedings of the National Academy of Sciences of the United States of America 1999 96 20 10958 10961 2-s2.0-0033613070 10.1073/pnas.96.20.10958 (Pubitemid 29487311)
12. Brenchley J. M., Price D. A., Schacker T. W., Asher T. E., Silvestri G., Rao S., Kazzaz Z., Bornstein E., Lambotte O., Altmann D., Blazar B. R., Rodriguez B., Teixeira-Johnson L., Landay A., Martin J. N., Hecht F. M., Picker L. J., Lederman M. M., Deeks S. G., Douek D. C., Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine 2006 12 12 1365 1371 2-s2.0-33845532053 10.1038/nm1511 (Pubitemid 44924494)
13. Marchetti G., Cozzi-Lepri A., Merlini E., Bellistrì G. M., Castagna A., Galli M., Verucchi G., Antinori A., Costantini A., Giacometti A., Di Caro A., D'Arminio Monforte A., Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011 25 11 1385 1394 2-s2.0-79959942490 10.1097/QAD.0b013e3283471d10
14. Soriano V., Puoti M., Sulkowski M., Cargnel A., Benhamou Y., Peters M., Mauss S., Bräu N., Hatzakis A., Pol S., Rockstroh J., Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007 21 9 1073 1089 2-s2.0-34248592912 10.1097/QAD.0b013e3281084e4d (Pubitemid 46763278)
15. Rower J. E., Meditz A., Gardner E. M., Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrobial Agents and Chemotherapy 2012 56 6 3011 3019 2-s2.0-84861108461 10.1128/AAC.06337-11
16. Anderson P. L., Kiser J. J., Gardner E. M., Rower J. E., Meditz A., Grant R. M., Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Journal of Antimicrobial Chemotherapy 2011 66 2 240 250 2-s2.0-78651417113 10.1093/jac/dkq447 dkq447
17. Kiser J. J., Aquilante C. L., Anderson P. L., King T. M., Carten M. L., Fletcher C. V., Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2008 47 3 298 303 2-s2.0-42049090195 10.1097/QAI. 0b013e31815e7478 (Pubitemid 351619414)
18. Boffito M., Acosta E., Burger D., Fletcher C. V., Flexner C., Garaffo R., Gatti G., Kurowski M., Perno C. F., Peytavin G., Regazzi M., Back D., Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Therapy 2005 10 3 375 392 2-s2.0-20444506418 (Pubitemid 41151016)
19. Ma Q., Zingman B. S., Luque A. E., Fischl M. A., Gripshover B. M., Venuto C. S., DiFrancesco R., Forrest A., Morse G. D., Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. Therapeutic Drug Monitoring 2011 33 3 309 314 10.1097/FTD.0b013e31821d3adb
20. Albrecht M., Lisa Mukherjee A., Tierney C., Morse G. D., Dykes C., Klingman K. L., Demeter L. M., A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clinical Trials 2011 12 4 201 214 10.1310/HCT1204-201
21. Haas D., Kuritzkes D., Ritchie M., Amur S., Gage B., Maartens G., Masys D., Fellay J., Phillips E., Ribaudo H., Freedberg K., Petropoulos C., Manolio T., Gulick R., Haubrich R., Kim P., Dehlinger M., Abebe R., Telenti A., Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of allergy and infectious diseases. HIV Clinical Trials 2011 12 5 277 285 10.1310/hct1205-277
22. Ribaudo H. J., Liu H., Schwab M., Schaeffeler E., Eichelbaum M., Motsinger-Reif A. A., Ritchie M. D., Zanger U. M., Acosta E. P., Morse G. D., Gulick R. M., Robbins G. K., Clifford D., Haas D. W., Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study. Journal of Infectious Diseases 2010 202 5 717 722 2-s2.0-77955685573 10.1086/655470
23. Morse G. D., Catanzaro L. M., Acosta E. P., Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. The Lancet Infectious Diseases 2006 6 4 215 225 2-s2.0-33645096370 10.1016/S1473-3099(06)70436-4
24. Decloedt E.H., Maartens G., Smith P., Merry C., Bango F., McIlleron H., The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS ONE 2012 7 3 e32173 10.1371/journal.pone.0032173
25. Kredo T., Mauff K., Van Der Walt J. S., Wiesner L., Maartens G., Cohen K., Smith P., Barnes K. I., Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrobial Agents and Chemotherapy 2011 55 12 5616 5623 10.1128/AAC.05265-11
26. Decloedt E. H., McIlleron H., Smith P., Merry C., Orrell C., Maartens G., Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrobial Agents and Chemotherapy 2011 55 7 3195 3200 2-s2.0-79959215519 10.1128/AAC.01598-10
27. Ren Y., Nuttall J. J. C., Eley B. S., Meyers T. M., Smith P. J., Maartens G., McIlleron H. M., Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. Journal of Acquired Immune Deficiency Syndromes 2009 50 5 439 443 2-s2.0-65449135183 10.1097/QAI.0b013e31819c33a3
28. Maponga C. C., Ma Q., Slish J. C., Morse G. D., HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Topics in HIV Medicine 2007 15 3 104 110 2-s2.0-34548166033
29. Hendrix C. W., Ying J. C., Fuchs E. J., Topical microbicides to prevent HIV: clinical drug development challenges. Annual Review of Pharmacology and Toxicology 2009 49 349 375 2-s2.0-65249168098 10.1146/annurev.pharmtox.48. 113006.094906
30. Heneine W., Kashuba A., HIV prevention by oral preexposure prophylaxis. Cold Spring Harbor Perspectives in Medicine 2012 2 3 a007419
31. Patterson K. B., Prince H. A., Kraft E., Jenkins A. J., Shaheen N. J., Rooney J. F., Cohen M. S., Kashuba A. D. M., HIV. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Science Translational Medicine 2011 3 112 112re4 10.1126/scitranslmed.3003174
32. Kashuba A. D., Patterson K. B., Dumond J. B., Cohen M. S., Pre-exposure prophylaxis for HIV prevention: how to predict success. The Lancet. In press 10.1016/S0140-6736(11)61852-7
33. Best B. M., Letendre S. L., Koopmans P., Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. Journal of Acquired Immune Deficiency Syndromes 2012 59 4 376 381
34. Prasitsuebsai W., Cressey T. R., Capparelli E., Vanprapar N., Lapphra K., Chokephaibulkit K., Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. Pediatric Infectious Disease Journal 2012 31 4 389 391 10.1097/INF.0b013e3182401c41
35. Rakhmanina N. Y., Capparelli E. V., Van Den Anker J. N., Personalized therapeutics: HIV treatment in adolescents. Clinical Pharmacology and Therapeutics 2008 84 6 734 740 2-s2.0-56549093153 10.1038/clpt.2008.187
36. Mahajan S. D., Aalinkeel R., Reynolds J. L., Nanotherapeutics using an HIV-1 poly A and transactivator of the HIV-1 LTR-(TAR-) specific siRNA. Pathology Research International 2011 2011 9 719139 10.4061/2011/719139
37. Meltzer M. S., Nakamura M., Hansen B. D., Turpin J. A., Kalter D. C., Gendelman H. E., Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Research and Human Retroviruses 1990 6 8 967 971 2-s2.0-0025003118 (Pubitemid 20300054)
38. Dong B. J., zheng Y., Hughes M. D., Frymoyer A., Verotta D., Lizak P., Sawe F., Currier J. S., Lockman S., Aweeka F. T., Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected Sub-Saharan African women. AIDS 2012 7 26 833 841
39. Vogler M. A., Patterson K., Kamemoto L., Park J. G., Watts H., Aweeka F., Klingman K. L., Cohn S. E., Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. Journal of Acquired Immune Deficiency Syndromes 2010 55 4 473 482 2-s2.0-78650788111 10.1097/QAI. 0b013e3181eb5ff5
40. Aweeka F. T., Stek A., Best B. M., Hu C., Holland D., Hermes A., Burchett S. K., Read J., Mirochnick M., Capparelli E. V., Lopinavir protein binding in HIV-1-infected pregnant women. HIV Medicine 2010 11 4 232 238 2-s2.0-77950825016 10.1111/j.1468-1293.2009.00767.x
41. Yilmaz A., Gisslén M., Spudich S., Lee E., Jayewardene A., Aweeka F., Price R. W., Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE 2009 4 9 2-s2.0-70149119217 10.1371/journal.pone.0006877 e6877